Cancer Breakthroughs. Realized. We help transform groundbreaking cancer-related research and innovation in Ontario into viable commercial opportunities that benefit patients, researchers, investors and Ontario's economy.
Entrepreneur adds US oncology management experience to Ontario commercialization.
Dr O’Neill brings two decades of cancer drug development and seed stage investment experience, as well as an extensive business network in pharma and biotech.
Dr. Laszlo Radvanyi's industry expertise & network aligns well with OICR and FACIT's shared vision.
FACIT looks forward to working with Dr. Radvanyi on translating Ontario’s breakthrough oncology innovations.
Restorative Breast Cancer Solution Start-Up Wins the 2018 FACIT Pitch Competition.
Biotechnology competition modeled after popular TV program Dragons' Den.
FACIT’s Prospects Oncology Fund invests $450k in promising Ontario breakthrough technologies.
Investment supports emerging entrepreneurial scientists and critical proof-of-principle studies.
Saying goodbye to FACIT's friend and visionary-in-chief.
Jeff was a fantastic leader in the OICR-FACIT family and the broader Ontario life sciences community.
Seeding world class oncology innovation: a look back at 2017
We hope 2017 was a prosperous year for you, our partners in health innovation. While FACIT had many successes this year.....
FACIT congratulates OICR on launching CTIP to drive Ontario's most promising cancer drugs towards the clinic.
The Clinical Therapeutics Innovation Pipeline (CTIP) will support the local translation of Ontario discoveries into therapies with the potential for improving the lives of patients with cancer. Ten projects were selected in this highly competitive funding round, and reflect the strength of the province’s collaborative network and drug discoveries.
FACIT expands Board to advance mandate to drive Ontario cancer breakthroughs.
New Trustees join existing Trustees, Mr. Greg Gubitz and Mr. John Morrison, bringing additional financial, entrepreneurial and biotech industry expertise.
FACIT Congratulates Portfolio Company Turnstone Biologics on Transformative Collaboration with AbbVie
Turnstone Biologics, a startup co-founded by FACIT, announced a research, option and license agreement with AbbVie Inc. for up to three of Turnstone's next-gen oncolytic viral immunotherapies. This partnership deepens the Ontario roots established by FACIT and its co-founders, expanding the scale of innovative research and local career opportunities for scientists.
Addition of new investors builds on Ontario’s next-gen radiotherapies and cancer innovations
FACIT congratulates Fusion on completing the second closing of their Series A, now oversubscribed at US$46M, with new investors joining including Adams Street Partners, Seroba Life Sciences, and Varian Medical Systems Inc. FACIT participated in both, this latest closing and as an early seed investor in Fusion.